Lilly Could See Generalized Anxiety Disorder Indication For Cymbalta In Early 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly submitted the sNDA for duloxetine’s new indication under a standard review.
You may also be interested in...
Cymbalta Buoyed By Branded Ad Campaign
Sales of Lilly’s antidepressant more than doubled in the first quarter.
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.
Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007
A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)